Targeting DNMT activity and altering DNA methylation patterns has emerged as a novel strategy in the utilization of miRNAs for HCC treatment, highlighting a growing area of research with significant therapeutic implications (Table 2). This evidence concerns the gene DNMT1 and hepatocellular carcinoma.